{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-040136","form_type":"8-K","ticker":"MTNB","cik":"0001582554","company_name":"Matinas BioPharma Holdings, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.635362+00:00","generated_at":"2026-06-08T06:41:57.954116+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Matinas BioPharma oral LNC docetaxel shows tumor reduction comparable to IV in melanoma model","bullets":["Oral LNC docetaxel reduced tumor volume 63% (high dose) and 57% (low dose) vs 68% for IV docetaxel at Day 14.","No systemic toxicity observed over 10 days; body weight and hematologic parameters stable.","Company plans further studies in other tumor models and longer treatment regimens to confirm safety.","Also plans to evaluate LNC formulations for small oligonucleotide anti-tumor activity."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-040136","json":"https://secwatch.observer/filing/0001493152-23-040136.json","markdown":"https://secwatch.observer/filing/0001493152-23-040136.md","text":"https://secwatch.observer/filing/0001493152-23-040136.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582554/000149315223040136/0001493152-23-040136-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582554/000149315223040136/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:41:57.954116+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}